Reuters logo
BRIEF-Immunovaccine says Princess Margaret Cancer Centre to conduct Phase 2 clinical trial to evaluate use of co, Merck's combination of immunotherapies
February 6, 2017 / 1:03 PM / 8 months ago

BRIEF-Immunovaccine says Princess Margaret Cancer Centre to conduct Phase 2 clinical trial to evaluate use of co, Merck's combination of immunotherapies

Feb 6 (Reuters) - Immunovaccine Inc :

* Immunovaccine’s lead immuno-oncology candidate to enter investigator-sponsored Phase 2 clinical trial in ovarian cancer in combination with approved anti-PD-1 drug

* Princess Margaret Cancer Centre to conduct Phase 2 clinical trial to evaluate use of combination of immunotherapies from co and Merck

* Expects to announce top-line interim results for Phase 1B trial of DPX-Survivac by end of March 2017

* In addition to Phase 2 trial, Immunovaccine is conducting a phase 1B trial with Incyte Corporation Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below